Gdansk

• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting
  2022-503055-26-00 9 2023-10-30 Unresectable recurrent or metastatic HPV16 (Human Papilloma Virus) pos
• A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting
  2022-502286-16-00 5 2023-10-27 Primary Generalized Tonic-Clonic Seizures
• Non-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mil … Recruiting
  2024-513214-34-00 4 2023-10-18 Distal Subungual Onychomycosis
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 5 2023-09-28 marginal zone lymphoma
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome Recruiting
  2023-505140-19-00 5 2023-07-31 Childhood Idiopathic Nephrotic Syndrome
• Open-label, long-term safety, efficacy, and pharmacokinetics study of vibegron in pediatric subjects 2 years to < 18 years of age with NDO a … Recruiting
  2024-513995-16-00 10 2023-07-28 Neurogenic Detrusor Overactivity (NDO)
• A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Ca … Recruiting
  2022-501703-27-00 5 2023-07-05 Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting
  2022-501427-24-00 4 2023-04-25 Nonadvanced Systemic Mastocytosis
• A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Recruiting
  2022-500391-62-00 9 2023-01-19 Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide … Recruiting
  2023-503795-24-00 7 2022-09-16 Avanced Non-Small Cell Lung Cancer
• Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia Gravis (AD … Recruiting
  2023-507379-23-00 10 2022-08-18 Generalized Myasthenia Gravis
• Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patie … Recruiting
  2022-501876-24-00 3 2022-06-17 Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
• A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting
  2023-505638-82-00 5 2022-01-12 Atypical Hemolytic Uremic Syndrome (aHUS)
• Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis Recruiting
  2024-511686-11-00 5 2021-10-05 Multiple Sclerosis in pediatric patients
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• A clinical study of different treatments for kidney cancer (MK-3475-03A) Recruiting
  2023-506838-68-00 9 2020-12-10 Renal cell carcinoma
• A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zos … Recruiting
  2022-502784-37-00 4 2019-09-03 Prevention of Herpes Zoster in immunocompromised subjects aged 1-17 ye
• A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC Recruiting
  2025-523602-33-00 9 2026-05-13 Advanced or unresectable Hepatocellular Carcinoma (HCC)

Showing 121–144 of 854 trials